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Growth factor-induced migration is a rate-limiting step in tumour invasiveness. The molecules that regulate this cellular behaviour
would represent novel targets for limiting tumour cell progression. Epidermal growth factor (EGF) receptor (EGFR)-mediated
motility, present in both autocrine and paracrine modes in prostate carcinomas, requires de novo transcription to persist over times
greater than a few hours. Therefore, we sought to define specific signalling pathways that directly alter cellular transcription. Signal
transducer and activator of transcription 3 (STAT3) is activated, as determined by electrophoretic motility shift assays, by EGFR in
DU145 and PC3 human prostate carcinoma cells in addition to the motility model NR6 fibroblast cell line. Inhibition of STAT3 activity
by antisense or siRNA downregulation or expression of a dominant-negative construct limited cell motility as determined by an in
vitro wound healing assay and invasiveness through a extracellular matrix barrier. The expression of constitutively activated STAT3 did
not increase the migration, which indicates that STAT3 is necessary but not sufficient for EGFR-mediated migration. These findings
suggest that STAT3 signalling may be a new target for limiting prostate tumour cell invasion. In a microarray gene analysis of what
transcription units are altered by EGF in a STAT3-dependent manner we found that the expression of motility-limiting VASP protein
and the apoptosis nexus caspase 3 were both downregulated upon EGF exposure. These findings suggest a molecular basis for the
STAT3 dependence of EGFR-mediated prostate tumour progression.
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Prostate cancer is the single most common form of solid tumour in
humans, present in more than 9 million men and is second only to
lung cancer in annual cancer deaths of US men (Landis et al, 1999).
Invasiveness into the adnexa by extension of the primary tumour
through the encapsulating matrix and musculature is a major
cause of morbidity and mortality or prostate cancer. This
invasiveness appears to be due to dysregulated motility (Wells
et al, 2002; Nguyen and Schrump, 2004). A subset of invasive cells
in the primary tumour must recognise and interact with the
surrounding extracellular matrix first, and then degrade or
remodel the ECM, and finally to migrate through it to reach
adjacent tissue. It was demonstrated that integrin-supported
motilities enables tumour invasion but growth factor-induced
motility promotes it (Rabinovitz and Mercurio, 1996; Gladson,
1999; Kassis et al, 2001). Thus, factors that enable this motility
would be points of intervention.
The epidermal growth factor receptor (EGFR) lies at the head of
a complex signal transduction cascade that contributes to a
number of processes important to cancer development and
progression. EGF-induced cell motility is important for tumour
invasion. In addition to a number of epigenetic signalling events, it
was found in fibroblasts that de novo transcription is required for
motility (Chen et al, 1994). One candidate pathway is that of STAT
(signal transducer and activator of transcription) proteins, a subset
of which are directly activated by EGFR independent of JAK
signalling or bridging (David et al, 1996). Seven mammalian STAT
genes have been found (STAT1, 2, 3, 4, 5a, 5b and 6) that are
structurally conserved. Full-length EGFR binds and directly
activates signal transducer and activator of transcription 1
(STAT1) and STAT3 (David et al, 1996); these function as homo-
and heterodimers (Stancito et al, 1996; Sato et al, 1997). These two
STATs have been considered repressors and promoters of
carcinogenic growth, respectively.
STAT3 activation is implicated in tumour invasion in head and
neck squamous cell and other carcinomas (Grandis et al, 1998;
Song and Grandis, 2000). A significant correlation has been
reported between the expression of nuclear STAT3 and breast
cancer as compared to normal mammary tissues (Berclaz et al,
2001). Interestingly, prostate tumour cells have been found to
contain constitutively activated STAT3, and blockade of this
activated STAT3 significantly suppressing the tumour cell growth
(Ni et al, 2000; Lee et al, 2004; Gao et al, 2005). This is of key
interest as a previous study already had demonstrated that
constitutively activated STAT3 can mediate cellular transformation
(Bromberg et al, 1999). A survey of organ-confined prostate
biopsies demonstrated a correlation between local aggressiveness
and phospho-STAT3 staining (Horinaga et al, 2005). These reports
support hypothesizing that STAT3 signalling contributes to
carcinogenic progression, in addition to merely increasing the cell
number.
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sHerein, we report that STAT3 signalling downstream from EGFR
autocrine activation leads to increase tumour cell motility and
invasiveness. Antisense and siRNA downregulation of STAT3
abrogated EGFR-mediated transcription signalling as evinced by
inhibition of electrophoretic mobility shift assay (EMSA) shift
detection. These interventions also blocked EGFR-mediated
fibroblast and DU145 and PC3 human prostate tumour cell
migration and transmigration of an ECM barrier, decreasing it to a
background level. Use of STAT3 dominant-negative (DN) and
constitutive active mutants in fibroblast and human prostate
tumour cells provided results consistent with the antisense
approach and demonstrated that while STAT3 signalling is
required it is not sufficient for the migratory and invasiveness
phenotype. Preliminary data on microarray and immunoblot
demonstrate a potential relationship between EGFR/STAT3
signalling pathway and the expression of ena/VASP and caspase
3, which related to cell motility and apoptosis, both key processes
in tumour progression.
MATERIALS AND METHODS
Cell lines and reagents
Human DU145 prostate carcinoma cells (Stone et al, 1978)
overexpressing EGFR, DU145WT (Xie et al, 1995), were main-
tained in DMEM supplemented with 10% FBS, L-glutamine (2mM),
nonessential amino acids (0.1mM), sodium pyruvate (1mM) and
100Uml
 1 of penicillin; 350mgml
 1 of G418 was added to the
medium for DU145WT cells. Human PC3 prostate cancer cells
(Kaighn et al, 1979) were maintained in F-12 medium supplemented
with 10% FBS, L-glutamine (2mM), nonessential amino acids
(0.1mM), and sodium pyruvate (1mM). Both prostate carcinoma
cell lines present active autocrine stimulatory loops involving EGFR
signalling, as is typical for de novo human prostate carcinomas
(Wells, 2000); we minimise this effect in vitro by altering culture
conditions, although this cannot be negated during the invasion
studies (Xie et al, 1995). For the biochemical studies, NR6WT mouse
fibroblasts expressing human EGFR (Wells et al, 1990) were
maintained in Eagle’s medium supplemented with 10% FBS, L-
glutamine (2mM), nonessential amino acids (0.1mM), sodium
pyruvate (1mM), 100Uml
 1 of penicillin and 350mgml
 1 of G418.
Oligonucleotides and transfections
STAT3 antisense oligonucleotides (Human: 50-CCA TTG GGC CAT
CCT GTT TCT-30, mouse: 50-GTT CCA CTG AGC CAT CCT GC-30)
were synthesised with phosphorothieate modification by DNA
synthesis facility of the University of Pittsburgh. SiRNA against
human STAT3 (50-GGAGCAGCACCUUCAGGAUTT-30), mouse
STAT3 (50-UGCAUGUCUCCUUGGCUCUUGAGGG-30) and eGFP
(50-ACCCGCGCCGAGGUGAAGTT-30) were from IDT (Skokie, IL,
USA). Transfections used the Lipofectamine 2000 method (Life
Technologies Inc). Cells were grown in antibiotic-free medium till
50–60% confluence and transfected with siRNA for 24h. The final
concentration of siRNA in the experiment is 100nM. After
transfection, the cells were allowed to recover in antibiotic free
medium for 24h before further experimentation. For these
experiments, the ‘no treatment’ control underwent mock transfec-
tion (no DNA added), the ‘control’ DNA was that from the other
species (e.g. the mouse sequence in human cells). From earlier
studies using eGFP, we found that this procedure resulted in
485% of the prostate caricnoma cells expressing the eGFP
plasmid (Mamoune et al, 2004).
Nuclear extract preparation and EMSA
For STAT3 analysis by EMSA (Sen and Baltimore, 1986), confluent
cells were harvested and washed with ice cold 1  PBS, with the
pellets resuspended in five-fold buffer A (10mM HEPES, pH 7.9;
1.5mM MgCl2;1 0m M KCl; 1mM NaF; 0.5mM DTT; 0.2mM PMSF;
1mgml
 1 popftain; 5mgml
 1 aprotinin; 2mgml
 1 leupeptin). After
incubating on ice for 15min, the nuclei were centrifuged at 41C for
10s. Pellets were resuspended in five-fold volumes (20ml–100ml)
cold buffer C (20mM HEPES, pH 7.9; 1.5mM MgCl2; 420mM NaCl;
10mM NaF; 1mM Na3VO4; 25% glycerol; 0.2mM EDTA; 0.5mM
DTT; 0.2mM PMSF; 1mgml
 1 popftain; 5mgml
 1 aprotinin;
2mgml
 1 leupeptin), incubated on ice for 30min and microcen-
trifuged for 2min at the maximum speed. Aliquots were stored at
 801C. For EMSA, 10mg of total extractions were used for each
experimental point. EMSA was performed using a g-
32P-labelled
double-strand oligonucleotide probe m67 (sense: 50-GAT TTC CCG
TAA ATC AT-30) that binds STAT3 and STAT1 proteins. Protein–
DNA complexes were resolved by nondenaturing PAGE gel and
detected by autoradiography. Anti-STAT3 antibodies (Upstate
Biotechnology, Waltham, MA, USA) were used for super shift
assay and a 50-fold excess of unlabelled m67 probe was used in
cold competition assay.
Migration assay
In vitro wound healing assay was used to assess cell motility in two
dimensions. Cells were plated on a 12-well plate and grown to
confluence in their regular medium. Confluent cells were quiesced
in 1% dialysed FBS for 24h before each experiment. A rubber
policeman was used to create a denuded area. Cells were washed
twice with PBS and treated with or without specific effectors for
24h. Photographs were taken at hours 0 and 24, and the distance
traveled was determined by subtracting the values obtained at hour
0 from 24. Mitomycin C (0.5mM) was added to the medium to
prevent the confounding issue of cell proliferation. The ‘no
treatment’ challenge was used to normalize each experiment and is
notated as a fractional level of 1.0.
Invasion assays
Invasive potential was determined in vitro by transmigration of an
ECM (Niedbala et al, 1985). Matrigel invasion chamber plates were
purchased from Becton Dickinson/Biocoat (Bedford, MA, USA).
The upper surface of the matrix was challenged with 1.5 10
4 cells,
a number derived from empirical experimentation. Cells were kept
in serum-free medium containing 1% BSA for the first 24h and
then replaced with only serum-free medium for the remaining
24h; the lower chamber contained medium containing 10% serum
for the entire assay. Enumeration of the cells that invaded through
the matrix over a 48h period was accomplished by visually
counting cells on the bottom of the filter, as per routine
procedures, after any uninvaded cells were removed from the
top of the filter with a cotton swab. In all of the cases, individual
experiments were performed in duplicate chambers. The ‘no
treatment’ challenge was used to normalize each experiment and is
notated as a fractional level of 1.0.
Immunoblotting
Protein expression was determined by immunoblotting using
standard means. Confluent cells were washed with ice cold 1 
PBS twice followed by treated with lysis buffer (100mM Tris-HCl,
pH 6.8; 4% SDS; 20% glycerol and 5% B-mercapto-ethanol). Sample
proteins were denatured at 1001C for 5min before loading to the gel.
After electrophoresis, the proteins were transferred to a Immobilon-
P membrane. Membranes were blocked by 1% BSA. After blocking,
membranes were incubated with a primary antibody: mouse anti-
STAT3 (Zymed, San Francisco, CA, USA); mouse anti-GAPDH
(abCam, Cambridge, MA, USA); mouse anti-Flag (Stratagene);
rabbit anti-phosphor-STAT3 (Cell Signaling, Danvers, MA, USA)
and rabbit anti-HA-tag (Cell Signaling) at 41C for overnight or at
STAT3 in EGFR-mediated motility
W Zhou et al
165
British Journal of Cancer (2006) 95(2), 164–171 & 2006 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sroom temperature for 1h. The membranes were washed twice with
0.5% Tween-20 (TBST) before incubated with secondary antibodies
(Goat anti-mouse Ig or Goat anti-rabbit Ig, Biosource, Carlsbad, CA,
USA) and detection as per standard procedures.
Cell counting
The cells proliferation and toxicity assay were preformed by direct
cell enumeration. A Z-series Coulter Counter (Coulter Corp.,
Miami, FL, USA) was used for the counting. Cells were digested by
Tripsin-EDTA (GiBco, Carlsbad, CA, USA) and the resuspended in
the original medium followed by a 1:100 dilution in Isoton II
solution (Beckman, Fullerton, CA, USA) for counting.
RESULTS
EGF activates STAT3 in fibroblasts and prostate carcinoma
cells
EGFR signalling activates STAT proteins in fibroblasts (David et al,
1996) and a variety of carcinoma cells (Grandis et al, 1998; Garcia
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Figure 1 EGF signalling induces STAT3 activity. (A) EMSA detects EGF-dependent STAT3 activity in NR6WT fibroblasts and DU145WT prostate
tumour cells. EMSA analysis of STAT3 DNA-binding activity in nuclear extracts prepared from mouse fibroblast cells and human prostate tumour cells using
the g-P
32-labelled m67 probe. Supershift with the STAT3 antibody shows the specificity of the STAT3 protein and cold competition demonstrates the
specificity of the m67 probe. Cells were treated with 10nM EGF, 10nM EGF plus 10mM STAT3 antisense or 10mM STAT3 antisense alone (cells were treated
14–18h). Lower concentrations of cold competition assays (10  and 5 ) were also preformed and showed the similar trending results (data not shown).
(B) Immunoblotting shows that EGF-mediated increase of STAT3 expression is suppressed by STAT3 antisense oligonucleotides, but not altered by
nonspecific oligonucleotides. (C) Immunoblotting shows that PD153035, an selective inhibitor of EGFR kinase, blocks the activation of STAT3 induced by
EGF in both DU145WT and PC3 cells. Also shown for in PC3 cells is that STAT3 siRNA suppresses the activity of STAT3. (D) EGF-mediated increase of
STAT3 expression and activity is suppressed by STAT3 siRNA in DU145WT cells, but not by random siRNA (against eGFP). The STAT3 siRNA also
negated EGF-induced STAT3 activity in DU145WT prostate tumour cells. Similar results were found with PC3 cells. Shown are representative blots of
experiments each performed at least three times.
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sand Jove, 1998; Bowman et al, 2000). As we have previously shown
that prostate carcinoma cells present autocrine EGFR signalling,
we determined whether this also invoked STAT3 activation. To
study this issue, we used the motility model system, murine
NR6WT fibroblasts, to examine EGF-triggered events as autocrine
signalling is absent in these cells in contrast to prostate carcinoma
cells which present autocrine EGFR-activating signalling loops,
and thus the role of EGFR signalling can be cleanly parsed. The two
human prostate cancer cell lines, DU145WT and PC3, present
autocrine activation of endogenous and exogenous EGFR, as is the
norm for prostate carcinoma cells. However, to parse the function
of EGFR signalling, we tested our prostate cells under conditions
that minimise autocrine activation (Xie et al, 1995).
In murine fibroblasts, NR6WT cells, EGF exposure increased
EMSA detection of the STAT3 band, which was upshifted upon
addition of an antibody to murine STAT3 (Figure 1A). In
DU145WT human prostate carcinoma cell lines, EGF increased
the STAT3-targeted band; herein the antibody to human STAT3
eliminated DNA binding (Figure 1A). We downregulated the
protein using antisense oligonucleotides or siRNA directed against
STAT3; these interventions reduced whole cell levels of STAT3
significantly in both NR6WT fibroblasts and DU145WT cells
(Figure 1B and D). Antisense and siRNA downregulation reduced
the EMSA detection in these cells. Similar findings were noted with
PC3 cells (data not shown). Further demonstrating the role of
EGFR signalling, the EGFR selective inhibitor PD153035 decreases
the effect of exogenous EGF on phosphorylation of STAT3
(Figure 1C); that this was not totally abrogated is due to the
limitations of using the inhibitor at concentrations that are
nontoxic. These findings demonstrate that STAT3 signalling is
present in prostate carcinoma cell lines in response to EGFR
signalling and that this signalling pathway increases STAT3
binding to target.
STAT3 is required for EGFR-mediated fibroblast and
human prostate tumour cell motility and invasiveness
EGFR signalling drives motility in fibroblasts and carcinoma cells
(Pedersen et al, 2004) and invasion of human prostate carcinoma
cells (Xie et al, 1995; Mamoune et al, 2004). Not surprisingly,
sustained motility also requires de novo RNA synthesis (Chen et al,
1994). As such, we asked whether STAT3 might be critical for
sustained motility and invasion in response to EGFR signalling. To
quantitate cell motility, an in vitro wound healing assay was
performed and demonstrated that the addition of STAT3 antisense
oligonucleotides and the EGFR signalling pathway inhibitor
PD153035 (Figure 2A) or siRNA-mediated downregulation
(Figure 2B) greatly decreased the migration distance of NR6WT
fibroblast cell and DU145WT and PC3 human prostate cancer cells.
The extent of migration inhibition was similar to that achieved by
blocking EGFR kinase activity with the selective agent PD153035.
Interestingly, the level of migration achieved with STAT3 down-
regulation, and with PD153035 was below that of basal motility,
strongly suggesting that either EGFR autocrine signalling via
STAT3 or basal STAT3 was contributing to this cell behaviour, as
has been implication earlier for EGFR autocrine activation (Xie
et al, 1995).
As motility is a key component to tumour cell invasion (Wells,
2000), we determined whether this inhibition affected tumour cell
invasion by examining the transmigration of a Matrigel barrier.
Both antisense oligonucleotides and siRNA directed against STAT3
limited tumour cell transmigration to below the levels noted in the
absence of added EGF (Figure 3). This extent of inhibition is
expected as both DU145WT and PC3 cells express EGFR ligands
(Maygarden et al, 1994), which generate autocrine stimulatory
signals in the physical confines of a matrix, and Matrigel contains
competent levels of EGFR ligands (Yudoh et al, 1994). That this is
due to EGFR signalling is shown by blockade using the selective
inhibitor PD153035 (Figure 3C). This inhibitor reduced not only
EGF-enhanced invasiveness but also the invasiveness in the
absence of exogenous EGF. Thus, during transmigration of
Matrigel the cells are in an active EGFR signalling mode.
STAT3 blockade has been found to lead to apoptosis in a
number of carcinoma cell lines; such a situation would confound
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Figure 2 STAT3 is required for EGF-receptor-mediated cell migration in
mouse fibroblast cells and human prostate tumour cells. (A) The migration
distance of NR6WT fibroblast and DU145WT prostate tumour cells after
treated with 1nM EGF for 24h was significantly greater and this increase
was suppressed by 10mM STAT3 antisense (S3AS) but not scrambled
nonspecific oligonucleotides (CtrlAS). Additionally, EGF-induced motility
was determined in the presence of the EGFR inhibitor PD153035 (PD15).
(B) The migration distance of DU145WT and PC3 prostate tumour cells
after treatment with 1nM EGF for 24h was significantly greater and this
increase was suppressed by STAT3 siRNA (S3Si) but not siRNA against
eGFP (CtrlSi). Shown are mean7s.e.m. for at least three experiments each
performed in triplicate. *Po0.01 compared to EGF treatment. The
migration distance (on the Y axis) is normalized to diluent alone (NoTx)
within each experiment.
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sour invasiveness studies. During the migration studies, we did not
note such effects morphologically. However, this was tested
directly for effects on cell number (Figure 3C). Downregulation
of STAT3 using siRNA did not reduce the number of DU145WT
cells and only slightly the PC3 cells. In parallel studies, we did not
note apoptosis in the absence of external stressor signals (data not
shown). Thus, studies on cell migration and invasiveness were not
confounded by changes in cell number due to STAT3 down-
regulation.
STAT3 signalling is not sufficient for motility
The foregoing data demonstrate that STAT3 activity is required for
increased cell migration and invasion upon EGFR signalling.
Upregulation of STAT3 levels in various cancers (Garcia et al,
1997; Bromberg et al, 1999; Bowman et al, 2000; Song and Grandis,
2000) might even suggest this functions as an ‘oncogene’ or
‘tumour progression’ gene. Thus, we asked whether upregulation
was sufficient to drive these behaviours. A constitutively active
(CA) STAT3 mutant failed (Kijima et al, 2002) to drive motility of
NR6WT cells in the absence EGF (Figure 4). A DN STAT3
construct did block EGF-induced motility, as expected. The STAT3
constructs were induced by dexamethasone to avoid adaptation or
cellular modifications during prolonged selection; the dexametha-
sone by itself had only a small negative effect on migration that
was minimal compared to the effects of either EGF or the
constructs. These data are consistent with STAT3 being required,
but not sufficient, for transcriptional activation of either replace-
ment proteins or modulation of the proteome at the transcriptional
to enable a locomotive state.
STAT 3 is required for EGFR-mediated expression of VASP
and caspase 3
STAT3 is well established as a transcription factor that alters the
global cell expressome. To further explore which proteins may
involve in the EGFR-STAT3 signalling pathway, we performed a
microarray analysis in NR6WT cells treated with EGF and/or
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Figure 3 STAT3 is critical for EGFR-mediated prostate tumour cell invasiveness. (A) STAT3 antisense (S3AS)-treated DU145WT cells have a much
lower invasion rate than those cells treated by EGF. (B) STAT3 siRNA (S3Si) inhibited EGFR-mediated invasion of both DU145WT and PC3 prostate
tumour cells, whereas eGFP-directed siRNA (CtrlSi) did not. (C) STAT3 siRNA downregulation did not significantly affect the number of DU145WT and
only somewhat reduced the number of PC3 human prostate cancer cells after 48h. However, this small decrement, if any, is minor compared to the effect
of such treatments on invasion. (D) PD153035 (1mM) blocked the EGF-induced invasiveness of the prostate carcinoma cells. For all experiments shown are
mean7s.e.m. for at least three experiments each performed in triplicate. *Po0.05 compared to EGF treatment. The invasiveness as determined by cell
number transmigrated through the Matrigel (on the Y axis) is normalized to diluent alone (NoTx) within each experiment.
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sSTAT3 antisense oligonucleotides. The mRNA species that under-
went STAT3-dependent, EGF-induced changes included some
intriguing targets (Supplemental Data). EGF downregulated ena/
VASP, which is a negative regulator of fibroblast cell motility,
(Bear et al, 2000). EGF also reduced the expression of caspase 3, a
central effector of apoptosis. The EGF-induced downregulation of
both proteins was abrogated by siRNA treatment of both NR6WT
and DU145WT cells (Figure 5). While these studies are just an
initial exploration of the underlying mechanisms of STAT3 effects
in prostate carcinoma cell invasiveness, they do suggest some
molecular effectors.
DISCUSSION
Carcinogenesis is a multistep process, in which cancer cells
disseminate from a localised primary tumour mass to both invade
adnexa and metastasize to distant organs. It has been well known
that tumour invasiveness is a distinct character of tumour
progression involving induced motility in addition to dysregulated
proliferation. As there’s no catholicon for the current anticancer
treatments, disrupting or at least inhibiting the tumour invasive-
ness would greatly ameliorate the morbidity and mortality. In this
study, we investigated whether activated STAT3 protein is involved
in the EGF-receptor-mediated migration in fibroblasts and human
prostate cancer cells and the invasiveness of the latter. EGF
increased STAT3 activity along with cell motility and invasiveness
of these cells. Decreased expression and activation of STAT3 by
treatment with STAT3 antisense oligo nucleotides or siRNA or in
the presence of a DN mutant of STAT3 abrogated migration and
invasion. The results together, indicated that STAT3 could be a
targeted critical element in the EGF-mediated cell migration and
invasion of prostate carcinoma cells.
Epigenetic events, in addition to transcriptome changes
signalled through STAT3, also contribute to tumour cell motility
and invasion. Comparing the migration of NR6WT cells expressing
constitutively activated STAT3 to those expressing the STAT3 DN
mutants, it is interesting to find that constitutively activated
STAT3 alone does not increase cell motility, nor does it increase
EGF-stimulated migration. This result suggests that STAT3 is not
sufficient for cell migration but that it provides for end effectors
that require additional signals for either activation or full
phenotypic expression. EGF stimulation of a cell results in the
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Figure 4 STAT3 is not sufficient for EGFR-mediated migration in NR6WT fibroblasts. (A) Immunoblotting demonstrates expression of STAT3 DN and
CA mutants in NR6WT cells upon transcriptional upregulation by dexamethasone. Shown are representative blots of at least three experiments each. (B)
The STAT3 CA mutant did not drive motility of NR6WT cells in the absence or presence EGF, while the DN construct blocked both basal and EGF-induced
motility, which indicates STAT3 is critical but not sufficient for the motility. Shown are mean7s.e.m. for at least three experiments each performed in
triplicate. *Po0.01 compared to EGF treatment. The migration distance (on the Y axis) is normalized to diluent alone of the empty vector (NoTx) within
each experiment.
NR6Wt
DU145WT
NoTx
VASP
Caspase 3
GAPDH
VASP
Caspase 3
GAPDH
EGF EGF/STAT3si EGF/Ctrl
NoTx EGF EGF/STAT3si EGF/Ctrl
Figure 5 EGF inhibits the expression of VASP and caspase 3 in both
NR6WT fibroblast cells and DU145WT human prostate tumour cells and
STAT3 siRNA recovered the expression of those two proteins back to a
normal level.
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sactivation of multiple pathways that lead to transcriptional control
including Src, PLCg, PI3-K, Ras/MAPK and JAK/STAT (Wells,
1999). These pathways are often functionally interlinked (Jorissen
et al, 2003). Thus, the need for de novo transcription and
translation that one notes during growth factor-induced motility
(Kislauskis et al, 1997; Mingle et al, 2005), can be accomplished by
a number of downstream transcription factors but requires STAT3
in addition to the previously determined PLCg pathway (Manos
et al, 2001; Mamoune et al, 2004). Recently, it has been noted that
EGFR signalling promotes progression of T24 bladder carcinoma
cells via STAT3 upregulation of transcription, including that of
matrix metaloproteinases (Itoh et al, 2006).
To further probe the role of the EGF/STAT3 pathway, an initial
microarray analysis was performed on NR6WT cells, thus avoiding
variable amounts of autocrine signalling, to determine transcripts
that were altered by EGF in a STAT3-dependent manner. (The
subset of these transcripts that are classified as related motility and
cell adhesion are provided in the Supplemental Table.) Interest-
ingly, these did not include the constituents of the well-known
epigenetic cascades but rather extracellular matrix or cell cyto-
skeleton components. It is possible that the enzymatic epigenetic
effects are regulated by the other EGFR-induced transcription
cascades, and that STAT3 primarily functions to provide the
motors and pathways for motility. Of note, we did not detect either
collagenase-1 (MMP-1) or stromelysin-2 (MMP-10) that was seen
to be upregulated in T24 bladder carcinoma cells (Itoh et al, 2006);
this discrepancy is likely due to our examining the nontrans-
formed NR6WT fibroblasts presenting a more limited set of trans-
cription changes, although the two changes noted in the fibroblasts
also were found in the cancer cells (Figure 5). Obviously, these
early hints are under active further investigation as these questions
lie beyond the scope of the current communication.
Recent studies suggest that aberrant STAT3 signalling may play
an important role in the carcinogenesis of prostate cancer.
Previous data from other groups shows higher phospho-STAT3
expression in prostate tumour tissues than in adjacent normal
tissues (Dhir et al, 2002; Mora et al, 2002), and that this correlates
with invasiveness (Horinaga et al, 2005). We also found increased
expression of STAT3 protein in prostate tumour tissues compared
to normal tissue from the same patient (data not shown, as similar
data have been previously published). It is quite reasonable that
the high expressed pSTAT3 in prostate tumour tissues is from the
increased expression of STAT3 as well as activation by autocrine
growth factor signalling (Song et al, 2001). Our study indicating
that STAT3 is critical for invasion of prostate cancer cells
DU145WT and PC3, secondary to increased cell motility is
consistent with these findings and provide for a mechanism by
which pSTAT exerts its effects.
Contrary to other studies (Barton et al, 2004; Pedranzini et al,
2004), we did not find decreased tumour cell numbers upon STAT3
downregulation (Figure 3); this may be due to the incomplete
nature of such interventions (although the other studies suffered
from similar nonquantitative abrogation), high levels of autocrine
EGFR signalling overcoming this limitation via other pathways, or
likely the shorter time course of our experiments. However, in
accord with these other studies, when we overexpressed the DN
STAT3 construct in DU145WT cells, we noted a high degree of
apoptosis in these cells (for the experiments in Figure 4, we
achieved a lower, non-apoptotic level of DN STAT3); our failure to
established stable clones expressing this DN construct likely relates
to this inhibition of proliferation and/or increased apoptosis. In
addition, when we stress the cells using apoptosis inducers the
blockade of STAT3 does increase tumour cell apoptosis. As such,
we feel that this discrepancy is more likely a quantitative rather
than a qualitative effect.
In sum, the model which emerges is one in which STAT3
signalling downstream from EGFR is required for persistent cell
motility and invasion, and that partial abrogation of this pathway
hinders this tumour progression. Only more extensive abrogation
of STAT3 signalling compromises carcinoma cell survival and
proliferation. Thus, STAT3 inhibition, even if suboptimal, would
slow tumour progression.
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